For the past 20 years there has been a growing epidemic resulting in radically unequal access to anti-retro viral drugs to treat HIV/AIDS. An epidemic that not only makes treatment unaffordable, but has also resulted in a situation where 90% of pharmaceutical research is directed at just 10% of the global disease burden. This in turn has led to the total neglect of some of the world’s deadliest diseases. Top of the list is HIV co-infection with Tuberculosis (TB), the main cause of death for HI...